- Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patents
- Recently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan
- The patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent family
- Lexaria also submitted a briefing book to the FDA to facilitate its upcoming pre-Investigational New Drug (“IND”) meeting with the agency
“We are extremely pleased to have received our first patent protecting our proprietary technology… I expect our intellectual property portfolio to continue to expand,” said Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka in an October 2016 press release announcing that the company had been issued U.S. Patent No. 9,474,725, Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof, by the U.S. Patent and Trademark Office (“USPTO”) (https://ibn.fm/iW3Ai).
Since receiving this patent, its first ever, which pertains to LEXX’s method of enhancing bioavailability and taste of specific cannabinoid lipophilic active agents in food products, the company has amassed an impressive portfolio worldwide that includes patents granted in India, Australia, Japan, the U.S., Mexico, and Europe, and is, in fact, still growing as its patent applications advance to granted patents. Lexaria is pursuing patent protection in over 40 countries and currently has roughly 50 pending patent applications globally (https://ibn.fm/R3jaO).
In a development that now pushes the number of granted patents worldwide to 26, Lexaria recently reported it had been notified of the allowance of a new patent to be granted in Japan, the fourth to be granted in that country. Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (“THC”) (https://ibn.fm/Hr8E2).
The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing gastric emptying time, or increasing splanchnic blood flow (https://ibn.fm/Udtkw). But DehydraTECH, Lexaria’s patented drug delivery technology, delivers drugs more consistently into the bloodstream regardless of this food effect. The drug delivery technology achieves this through its use of fatty acid oil.
Lexaria’s technology joins the API’s molecules in what is believed to be a “barbell-shaped” structure that allows the body to detect both molecules while enhancing taste and absorption. The body’s detection and natural processing of the long chain fatty acid is part of Lexaria’s clever patented process that also enhances the API absorption.
Bioavailability refers to both absorption levels and the time required to absorb. “In order to feel something quickly, you need to avoid something that’s known as fast-pass liver metabolism. When you eat food, it goes into your stomach, then it goes into your intestine, and then most of the nutrients go into your liver for filtration before they get into the bloodstream. That takes about an hour and a half, on average. But [using] our technology, we are able to divert the molecules away from the liver, and that allows you to get feelings or experiences in as little as 15 to 20 minutes,” Chris Bunka continued.
Meanwhile, Lexaria also reported it had submitted its briefing book to the U.S. Food and Drug Administration (“FDA”). This documentation will facilitate a pre-Investigational New Drug (“IND”) meeting that LEXX had requested in an early June letter to the FDA. The FDA provided a target date of July 30, 2022, for a meeting or comments.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content
